| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TRSL.2011.12.003 |
| P698 | PubMed publication ID | 22633099 |
| P50 | author | Ignazio Barbagallo | Q47757242 |
| Fabio Galvano | Q30512663 | ||
| Francesco Cappello | Q37843560 | ||
| P2093 | author name string | Giovanni Li Volti | |
| Federico Salamone | |||
| Andrea Mangiameli | |||
| P2860 | cites work | Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C. | Q46610601 |
| Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis | Q46648168 | ||
| Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury | Q46726944 | ||
| NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis | Q46802365 | ||
| Extraction of tissue long-chain acyl-CoA esters and measurement by reverse-phase high-performance liquid chromatography. | Q51636654 | ||
| Iron-induced oxidant stress leads to irreversible mitochondrial dysfunctions and fibrosis in the liver of chronic iron-dosed gerbils. The effect of silybin. | Q54314248 | ||
| Hepatocyte Apoptosis, Expression of Death Receptors, and Activation of NF-κB in the Liver of Nonalcoholic and Alcoholic Steatohepatitis Patients | Q57760193 | ||
| Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease | Q59448024 | ||
| Treating fatty liver for the prevention of cardiovascular diseases | Q60023183 | ||
| Nuclear factor-kappaB inhibition and non-alcoholic steatohepatitis: inflammation as a target for therapy. | Q61763019 | ||
| Antioxidant activity of silybin in vivo during long-term iron overload in rats | Q71584393 | ||
| Scavenging of reactive oxygen species by silibinin dihemisuccinate | Q72174184 | ||
| A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease | Q95000126 | ||
| Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis | Q24625697 | ||
| A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding | Q25938984 | ||
| Purification and properties of acyl-CoA oxidase from rat liver | Q28282715 | ||
| Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity | Q28297290 | ||
| Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study | Q34501554 | ||
| Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice | Q35153847 | ||
| iNOS-mediated nitric oxide production and its regulation | Q35789162 | ||
| Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet | Q36558384 | ||
| The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury | Q36571400 | ||
| Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases | Q36572087 | ||
| Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis | Q36895504 | ||
| Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects | Q37068823 | ||
| Peroxynitrite detoxification and its biologic implications. | Q37171996 | ||
| Redox regulation of nuclear post-translational modifications during NF-kappaB activation | Q37388619 | ||
| Histopathology of non-alcoholic fatty liver disease | Q37612118 | ||
| Fatty liver and lipotoxicity | Q37621647 | ||
| The role of oxidative stress in non-alcoholic steatohepatitis | Q37868177 | ||
| Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice | Q38310192 | ||
| Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin | Q38338847 | ||
| Inhibition of inducible nitric-oxide synthase expression by silymarin in lipopolysaccharide-stimulated macrophages | Q40724940 | ||
| Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase | Q42563412 | ||
| A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations | Q42844656 | ||
| Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. | Q42981378 | ||
| A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. | Q43223041 | ||
| Silibinin protects mice from T cell-dependent liver injury | Q44555689 | ||
| Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients | Q44615824 | ||
| Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice | Q45175704 | ||
| Liver NF-kappaB and AP-1 DNA binding in obese patients | Q46150605 | ||
| Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1. | Q46254429 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 477-486 | |
| P577 | publication date | 2012-01-02 | |
| P1433 | published in | Translational Research | Q15761127 |
| P1476 | title | Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis | |
| P478 | volume | 159 |
| Q36432198 | Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study |
| Q47074172 | Cannabinoid receptor 1 promotes hepatic lipid accumulation and lipotoxicity through the induction of SREBP-1c expression in zebrafish |
| Q58765669 | Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD |
| Q35293633 | Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model. |
| Q51503602 | Dietary silymarin supplementation promotes growth performance and improves lipid metabolism and health status in grass carp (Ctenopharyngodon idellus) fed diets with elevated lipid levels. |
| Q92219939 | Differential Effects of Silibinin A on Mitochondrial Function in Neuronal PC12 and HepG2 Liver Cells |
| Q41122488 | Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis |
| Q41817046 | Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis |
| Q36112852 | Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials |
| Q35107757 | Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells |
| Q38992949 | Genetic ablation of macrohistone H2A1 leads to increased leanness, glucose tolerance and energy expenditure in mice fed a high-fat diet |
| Q40641829 | Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy |
| Q93016049 | Herbal drug discovery for the treatment of nonalcoholic fatty liver disease |
| Q35753386 | Hugan Qingzhi Exerts Anti-Inflammatory Effects in a Rat Model of Nonalcoholic Fatty Liver Disease |
| Q45061974 | Human germline hedgehog pathway mutations predispose to fatty liver. |
| Q21133747 | Immunopositivity for histone macroH2A1 isoforms marks steatosis-associated hepatocellular carcinoma |
| Q35415945 | LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD). |
| Q50289688 | Magnolol Alleviates Inflammatory Responses and Lipid Accumulation by AMP-Activated Protein Kinase-Dependent Peroxisome Proliferator-Activated Receptor α Activation |
| Q54961894 | Mediterranean diet and nonalcoholic fatty liver disease. |
| Q42072118 | NAFLD and Atherosclerosis Are Prevented by a Natural Dietary Supplement Containing Curcumin, Silymarin, Guggul, Chlorogenic Acid and Inulin in Mice Fed a High-Fat Diet |
| Q51314344 | Nitric oxide as a protector from nonalcoholic fatty liver disease. |
| Q28248994 | Non-alcoholic fatty liver disease: need for a balanced nutritional source |
| Q43210750 | Nuciferine downregulates Per-Arnt-Sim kinase expression during its alleviation of lipogenesis and inflammation on oleic acid-induced hepatic steatosis in HepG2 cells |
| Q47280001 | Picroside II attenuates fatty acid accumulation in HepG2 cells via modulation of fatty acid uptake and synthesis |
| Q64246222 | Potential Role of Flavonoids in Treating Chronic Inflammatory Diseases with a Special Focus on the Anti-Inflammatory Activity of Apigenin |
| Q58753073 | Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD |
| Q57269401 | Reversing effects of silybin on TAA-induced hepatic CYP3A dysfunction through PXR regulation |
| Q33765372 | Serum oxidative stress markers and lipidomic profile to detect NASH patients responsive to an antioxidant treatment: a pilot study |
| Q40033823 | Silibinin Regulates Lipid Metabolism and Differentiation in Functional Human Adipocytes |
| Q45531739 | Silibinin Restores NAD⁺ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver. |
| Q38901272 | Silibinin improves palmitate-induced insulin resistance in C2C12 myotubes by attenuating IRS-1/PI3K/Akt pathway inhibition |
| Q33852271 | Silibinin inhibits ICAM-1 expression via regulation of N-linked and O-linked glycosylation in ARPE-19 cells |
| Q37290054 | Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor. |
| Q39027675 | Targeting Inflammation in Cancer Prevention and Therapy |
Search more.